Sanofi
After 15 years at Merck, Belén Garijo is leaving the company and will take over as CEO of Sanofi at the end of April 2026. Her term as chair of Merck's Executive Board will end as planned, and Kai Beckmann from within the company will take over as her successor. This means that changes are in store at the top of both Merck and Sanofi. Paul Hudson will leave Sanofi in mid-February 2026.
Sanofi is restructuring its vaccine logistics in France and transferring the operation of its distribution center in Val-de-Reuil to DHL Supply Chain. The aim is to make storage and distribution processes more efficient and resilient. The collaboration builds on a long-standing partnership and strengthens the pharmaceutical supply chain for the global market.
Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases. In addition, the acquisition of Blueprint brings Sanofi an established presence among...
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences...
Sanofi announced that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. The company warmly thanks Dr. Reed for his leadership over these last years. Since joining Sanofi in 2018, John has laid the foundation for the company’s R&D transformation. He helped reshape Sanofi’s discovery and development of therapeutics, focusing efforts on...
In early 2023, Sanofi Ventures received a commitment from its parent company for an additional multi-year commitment. The capital will be increased to more than 750 million dollar for the "evergreen venture fund." This venture capital fund focuses on early-stage investments, co-creating companies and leading financing rounds. The venture capital firm seeks to further expand its investments by...
Pharmaceutical company Sanofi has presented strong results for the first quarter of 2022. Sales grew by around 13 percent to 9.7 billion euros. Exchange rate fluctuations had a positive impact, mainly due to the dollar. Overall, the French company benefited from good business with its neurodermatitis and asthma drug from January to March 2022, but business with over-the-counter medicines showed...
Sanofi has named four new leaders to its Executive Committee. These appointments now complete the announced changes in February to further simplify the Company’s executive leadership team. The complete Sanofi Executive Committee now includes the four heads of the Company’s global business units (Sanofi Genzyme, Sanofi Pasteur, General Medicines, and Consumer Healthcare) as well as the global Heads...
Sanofi Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a Sars vaccine which may unlock a fast path forward for developing a Covid-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (Barda), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company’s long...
Sanofi and Alnylam have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran, as previously announced, will continue unchanged.
